Ind-Swift gets nod for proposed scheme of amalgamation

18 Nov 2011 Evaluate

Ind-Swift has received an approval for the proposed scheme of amalgamation of Essix Biosciences and Dashmesh Medicare with itself. The board at its meeting held on November 14, 2011 has granted its in-principle approval for the same.

The amalgamation will be done under section 391 to 394 of the Companies Act, 1956, subject to appropriate statutory and regulatory approvals.

Essix Biosciences and Dashmesh Medicare are both unlisted entities.

Ind-Swift manufactures and markets finished dosage forms, through its different divisions, focusing on the needs of various therapeutic segments. The divisions include Super Speciality, Animal Division, Daignozis, Institutions, Agile, Bio Sciences, Ethical, Health Care, Max Care, Mega care, Neuro and Resurgence.

Ind-Swift - Amalgama Share Price

15.70 0.00 (0.00%)
13-Aug-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×